XOMA Corp
NASDAQ:XOMA

Watchlist Manager
XOMA Corp Logo
XOMA Corp
NASDAQ:XOMA
Watchlist
Price: 30.2 USD 0.43% Market Closed
Market Cap: 355.8m USD
Have any thoughts about
XOMA Corp?
Write Note

XOMA Corp
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

XOMA Corp
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
XOMA Corp
NASDAQ:XOMA
Pre-Tax Income
-$38.6m
CAGR 3-Years
N/A
CAGR 5-Years
-119%
CAGR 10-Years
7%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

XOMA Corp
Glance View

Market Cap
355m USD
Industry
Biotechnology

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

XOMA Intrinsic Value
34.96 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is XOMA Corp's Pre-Tax Income?
Pre-Tax Income
-38.6m USD

Based on the financial report for Sep 30, 2024, XOMA Corp's Pre-Tax Income amounts to -38.6m USD.

What is XOMA Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
7%

Over the last year, the Pre-Tax Income growth was -44%.

Back to Top